ixazomib - Robuta Search

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-ixazomib-lenalidomide-and-dexamethasone-for-people-with-myeloma-fitness A trial of ixazomib, lenalidomide and dexamethasone for people with myeloma (FITNEsS) This trial is for people who might not be able to have the full dose of treatment because they have other illnesses or are not fit enough. a trial https://www.takeda.com/en-ca/newsroom/2015/multiple-myeloma-phase3-study/ Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for ixazomib, First and Only Once-Weekly... Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for ixazomib, First and Only Once-Weekly Oral Proteasome Inhibitor for Multiple Myeloma https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1521432/full Frontiers | Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in... Proteasome inhibitors can eliminate malignant, alloreactive, or autoreactive plasma cells. These cells are key players in antibody-mediated autoimmune disord... myasthenia gravis frontiers efficacy ixazomib https://www.medlineplus.gov/druginfo/meds/a616008.html Ixazomib: MedlinePlus Drug Information Ixazomib: learn about side effects, dosage, special precautions, and more on MedlinePlus ixazomib medlineplus drug information https://www.takeda.com/newsroom/newsreleases/2019/phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation/ Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in... Phase 3 Trial of NINLARO (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell... https://www.muni.cz/vyzkum/publikace/2431577 Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed... efficacy ixazomib lenalidomide dexamethasone regimen https://www.takeda.com/newsroom/newsreleases/2014/takedas-investigational-oral-proteasome-inhibitor-ixazomib-granted-breakthrough-therapy-designation-by-us-fda-for-relapsed-or-refractory-systemic-light-chain-amyloidosis/ Takeda's Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy... Takeda's Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic... proteasome inhibitor takeda oral ixazomib granted https://www.takeda.com/newsroom/newsreleases/2016/takeda-receives-positive-chmp-opinion-for-conditional-approval-of-ninlaro/ Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLARO (ixazomib), the First... Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLARO (ixazomib), the First Oral Proteasome Inhibitor, for Use in Patients with Multiple...